Supplementary Table 1: Perioperative vital signs\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Items | Aspirin Group | Rivaroxaban Group | Statistics | *P* |
| SBP (mmHg) |  |  |  |  |
| Before surgery | 115.29±10.46 | 114.75±9.63 | 0.23 | 0.82 |
| POD 1 | 116.68±10.74 | 117.47±9.14 | -0.33 | 0.74 |
| At discharge | 118.76±9.95 | 119.06±9.07 | -0.13 | 0.90 |
| DBP (mmHg) |  |  |  |  |
| Before surgery | 78.65±5.69 | 79.19±5.31 | -0.42 | 0.68 |
| POD 1 | 78.12±5.44 | 79.08±4.93 | -0.78 | 0.44 |
| At discharge | 78.65±5.92 | 80.11±4.79 | -1.13 | 0.26 |
| HR (bpm) |  |  |  |  |
| Before surgery | 80.53±11.31 | 78.67±11.24 | 0.69 | 0.49 |
| POD 1 | 80.03±6.39 | 78.28±6.33 | 1.15 | 0.25 |
| At discharge | 81.44±10.08 | 80.03±10.85 | 0.56 | 0.58 |
| SpO2 (%) |  |  |  |  |
| Before surgery | 98.68±0.91 | 98.78±0.83 | -0.48 | 0.63 |
| POD 1 | 98.94±0.69 | 99.03±0.61 | -0.55 | 0.58 |
| At discharge | 99.18±0.83 | 98.94±0.83 | 1.17 | 0.25 |

Data was presented as mean ± standard deviation. \* *t-*test for normally distributed data. SBP:systolic blood pressure; DBP:diastolic blood pressure; HR:heart rate; SpO2: oxygen saturation; POD: postoperative day.

Supplementary Tabel 2: Laboratory bloodwork between aspirin group and rivaroxaban group before operation and postoperation.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Items | Aspirin group  (n=34) | Rivaroxaban group  (n=36) | Statistics | *P* |
| Hemoglobin |  | | | |
| PRE | 130.5 (125.0–142.0) | 135.5 (124.0–148.8) | 0.62 | 0.53 |
| POD 1 | 116.0 (104.0–128.0) | 106.5 (100.3–116.8) | -1.93 | 0.04 |
| POD 3 | 109.0 (91.3–115.5) | 91.0 (86.3–107.8) | -2.06 | 0.04 |
| POD 5 | 111.0 (101.3–117.3) | 103.5 (92.3–112.0) | -2.32 | 0.02 |
| POD 30 | 126.0 (114.5–135.0) | 123.0 (114.5–143.0) | 0.18 | 0.86 |
| PLT (109/L) |  | | | |
| PRE | 236.5 (183.8–280.0) | 234.0 (188.8–299.3) | 0.72 | 0.47 |
| POD 1 | 206.0 (173.8–248.8) | 224.0 (174.5–282.3) | 0.70 | 0.48 |
| POD 3 | 196.0 (165.0–248.5) | 196.5 (154.0–237.0) | -0.53 | 0.60 |
| POD 5 | 218.0 (150.3–279.2) | 215.5 (135.8–244.8) | -0.47 | 0.64 |
| POD 30 | 237.5 (182.0–280.5) | 233.0 (181.3–277.3) | -0.04 | 0.97 |
| HCT (%) |  | | | |
| PRE | 38.8 (36.9–41.4) | 40.4 (37.6–43.1) | 1.69 | 0.09 |
| POD 1 | 35.0 (32.2–38.4) | 32.2 (29.5–33.5) | -3.42 | <0.01 |
| POD 3 | 32.8 (29.3–35.2) | 27.2 (25.9–31.6) | -3.29 | <0.01 |
| POD 5 | 35.5 (31.6–37.8) | 32.5 (28.7–35.7) | -2.70 | <0.01 |
| POD 30 | 39.6 (35.1–41.4) | 38.6 (36.0–41.8) | -0.07 | 0.95 |
| CRP (mg/L) |  | | | |
| PRE | 2.3 (1.2–6.2) | 2.5 (1.1–5.3) | -0.17 | 0.86 |
| POD 1 | 34.3 (17.6–53.5) | 33.2 (15.1–65.6) | -0.32 | 0.75 |
| POD 3 | 88.6 (63.0–117.8) | 87.8 (56.5–109.5) | -0.16 | 0.87 |
| POD 5 | 55.5 (49.1–73.5) | 70.6 (52.9–79.5) | 1.36 | 0.17 |
| POD 30 | 10.5 (3.5–12.6) | 5.3 (3.4–10.2) | -1.28 | 0.20 |
| ESR (mm/h) |  | | | |
| PRE | 13.5 (7.0–21.0) | 11.5 (7.3–17.0) | -0.95 | 0.34 |
| POD 1 | 18.0 (12.0–30.5) | 13.0 (10.0–23.0) | -2.00 | 0.05 |
| POD 3 | 56.0 (47.3–69.0) | 53.0 (44.0–70.8) | -0.42 | 0.68 |
| POD 5 | 53.5 (44.8–67.5) | 52.5 (39.8–67.8) | -0.04 | 0.97 |
| POD 30 | 18.0 (13.8–26.3) | 19.0 (13.5–30.3) | 0.20 | 0.84 |
| D-Dimer (mg/L) |  | | | |
| PRE | 0.4 (0.2–0.6) | 0.3 (0.2–0.5) | -1.70 | 0.09 |
| POD 1 | 5.6 (3.1–10.2) | 3.3 (2.0–7.6) | -1.51 | 0.13 |
| POD 3 | 2.2 (1.4–2.9) | 1.7 (1.2–2.5) | -1.08 | 0.28 |
| POD 5 | 4.5 (3.2–5.1) | 4.0 (3.0–5.1) | -0.98 | 0.32 |
| POD 30 | 1.4 (0.9–2.6) | 1.7 (0.9–2.4) | 0.36 | 0.72 |

Data was presented as “median (interquartile range)”. PLT, platelet; HCT, hematocrit; CRP, C-reaction protein; ESR, erythrocyte sedimentation rate; POD, postoperative day; PRE, pre-operation.